Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure

Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).

Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.

Inclusion Criteria:

• had repeated implantation failure
• have at least 1 good quality embryo for transfer

Exclusion Criteria:

• uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)